Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
Year: 2024
Type: article
Study design: Observational Study
Abstract: Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp's real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.
Source: Acta Dermato Venereologica
Authors: Lucille Vitek, Thomas Goronflot, Caroline Dutriaux, Antoine Deleuze, Yannick Le Corre, Anne-Bénédicte Duval-Modeste, Cécile Fresnard, Géraldine Jeudy, Anouck Lamoureux, Caroline Gaudy-Marqueste, Delphine Legoupil, Barouyr Baroudjian, Jean-Matthieu L'Orphelin, Lucie Peuvrel, Amir Khammari, Laurent Mortier, Gaëlle Quereux
Institutions: Centre Hospitalier Universitaire de Nantes, Inserm, Centre d'Investigation Clinique de Nantes, Nantes Université, Hôpital Saint-André, Centre Eugène Marquis, Centre Hospitalier Universitaire d'Angers, Université de Rouen Normandie, Centre Hospitalier de La Rochelle, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Centre Hospitalier Régional Universitaire de Brest, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Caen Normandie, Institut de Cancérologie de l'Ouest, Immunologie et Nouveaux Concepts en Immunothérapie, Centre Hospitalier Universitaire de Lille
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,725
OpenAlex ID: W4405383050